pros and cons of glp-1 agonist The Benefits Therapy: Beyond Weight Loss Mapping the effectiveness and risks
Description
2021;9 doi: 10.1177/23247096211051919
At the end of the original 72-week study, people on the highest dose of either medication were randomized into two arms: the treatment group taking a once-daily dose of orforglipron and a placebo control group
Tirzepatide has the potential to prevent atherosclerosis risk in T2DM patients without pre-existing lesions
Current Medical Research and Opinion
Overall, anti-metabolic drugs performed the best in both aspects, with odds ratios of 2.15 and 1.35, while anti-fibrotic drugs showed ratios of 0.86 and 1.11
